Anti-inflammatory properties of marine lipid compositions

Abstract

Novel marine lipid compositions comprising triglycerides and omega-3 rich phospholipids are described. The compositions are characterized by providing highly bioavailable omega-3, increased tissue incorporation of omega-3 and reduced concentration of pro-inflammatory cytokines.

1 . (canceled) 
     
     
         2 . A method of improving cognitive performance in a mammalian subject comprising administering to the subject a lipid composition comprising a mixture of phospholipid molecules, having the following general structure: 
       
         
           
           
               
               
           
         
       
       wherein R1 and R2 are a fatty acid residue or —OH and R1 and R2 are not simultaneously —OH and R3 is a choline, ethanolamine, serine or inositol group and said mixture of phospholipid molecules is characterized in comprising at least 1% docosahexaenoic acid (DHA) residues or eicosapentaenoic acid (EPA) residues at positions R1 or R2, said lipid composition has a lysophospholipid content of from 15% to 60% w/w of said composition, and said composition comprises triglycerides. 
     
     
         3 . The method of  claim 2 , wherein the mammalian subject is human. 
     
     
         4 . The method of  claim 2 , wherein the mammalian subject is a companion animal. 
     
     
         5 . The method of  claim 2 , wherein the improved cognitive performance is reduced memory loss. 
     
     
         6 . The method of  claim 2 , wherein the improved cognitive performance is reduced forgetfulness. 
     
     
         7 . The method of  claim 2 , wherein the improved cognitive performance is a reduction of short-term memory loss. 
     
     
         8 . The method of  claim 2 , wherein the improved cognitive performance is a reduction in aphasia. 
     
     
         9 . The method of  claim 2 , wherein the improved cognitive performance is a reduction is disorientation. 
     
     
         10 . The method of  claim 2 , wherein the improved cognitive performance is a reduction in disinhibition. 
     
     
         11 . The method of  claim 2 , wherein the mammalian subject mammal has symptoms of age-associated memory impairment or decline. 
     
     
         12 . A method of improving cognitive performance in a human subject comprising administering to the subject a lipid composition comprising a mixture of phospholipid molecules, having the following general structure: 
       
         
           
           
               
               
           
         
       
       wherein R1 and R2 are a fatty acid residue or —OH and R1 and R2 are not simultaneously —OH and R3 is a choline, ethanolamine, serine or inositol group and said mixture of phospholipid molecules is characterized in comprising at least 1% docosahexaenoic acid (DHA) residues or eicosapentaenoic acid (EPA) residues at positions R1 or R2, said lipid composition has a lysophospholipid content of from 15% to 60% w/w of said composition, and said composition comprises triglycerides, and
 wherein the human subject has symptoms of age-associated memory impairment or decline. 
 
     
     
         13 . The method of  claim 12 , wherein the improved cognitive performance is reduced memory loss. 
     
     
         14 . The method of  claim 12 , wherein the improved cognitive performance is reduced forgetfulness. 
     
     
         15 . The method of  claim 12 , wherein the improved cognitive performance is a reduction of short-term memory loss. 
     
     
         16 . The method of  claim 12 , wherein the improved cognitive performance is a reduction in aphasia. 
     
     
         17 . The method of  claim 12 , wherein the improved cognitive performance is a reduction is disorientation. 
     
     
         18 . The method of  claim 12 , wherein the improved cognitive performance is a reduction in disinhibition.